Analyst Ratings For Myriad Genetics (NASDAQ:MYGN)
Today, Goldman Sachs Group initiated coverage on Myriad Genetics (NASDAQ:MYGN) with a Sell.
Some recent analyst ratings include
- 1/29/2018-Goldman Sachs Group initiated coverage with a Sell rating.
- 10/2/2017-Leerink Swann Reiterated Rating of Mkt Perform .
- On 1/22/2018 Richard M Marsh, VP, sold 37,654 with an average share price of $40.25 per share and the total transaction amounting to $1,515,573.50.
- On 1/18/2018 Gary A King, VP, sold 3,120 with an average share price of $38.12 per share and the total transaction amounting to $118,934.40.
- On 1/12/2018 Richard M Marsh, VP, sold 13,759 with an average share price of $36.25 per share and the total transaction amounting to $498,763.75.
- On 12/14/2017 Walter Phd Gilbert, Director, sold 7,500 with an average share price of $33.19 per share and the total transaction amounting to $248,925.00.
- On 12/11/2017 Heinrich Dreismann, Director, sold 6,000 with an average share price of $33.50 per share and the total transaction amounting to $201,000.00.
- On 11/13/2017 Alexander Ford, Insider, sold 3,031 with an average share price of $31.64 per share and the total transaction amounting to $95,900.84.
- On 9/1/2017 John T Henderson, Director, sold 30,000 with an average share price of $30.30 per share and the total transaction amounting to $909,000.00.
Recent Trading Activity for Myriad Genetics (NASDAQ:MYGN)
Shares of Myriad Genetics closed the previous trading session at 38.66 down -2.35 5.73% with 39.029998779296875 shares trading hands.